Industry-Sponsored Research Week
Industry-Sponsored Research Management

Brigham and Women’s Hospital in new sponsored research deal with Spotlight Innovation to develop spinal muscular atrophy therapies


By David Schwartz
Published: July 11th, 2017

Brigham and Women’s Hospital has inked a sponsored research agreement with Spotlight Innovation Inc., which will focus on developing drugs to treat patients with spinal muscular atrophy (SMA).

The research will be overseen by Kevin Hodgetts, PhD, who is a member of Spotlight Innovation’s Scientific Advisory Board and co-inventor of STL-182, the company’s lead product candidate for SMA. He is the head of Medicinal Chemistry and Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) at Brigham and Women’s Hospital and Assistant Professor of Neurology at Harvard Medical School.

Geoffrey Laff, PhD, Spotlight Innovation’s senior VP of business development, commented, “Professor Hodgetts is an accomplished medicinal chemist and a pioneer in the synthesis of novel compounds with the potential to treat SMA. We are thrilled that he has chosen to collaborate with us to develop treatments for this devastating illness.”

Source:  PR Newswire

Posted under: Industry-Sponsored Research Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment